<DOC>
	<DOCNO>NCT02695992</DOCNO>
	<brief_summary>The RATAF II study randomize , prospective , parallel group study , design compare effect two different drug regimen rate control permanent AF ( atrial fibrillation ) . We investigate difference effect exercise capacity , biomarkers ( NT-proBNP ( N-terminal pro-brain natriuretic peptide ) , troponins , hs-CRP ) , heart rate , echocardiographic measurement symptom . Our main hypothesis six month ' treatment calcium channel blocker diltiazem low NT-proBNP increase exercise capacity ( peak VO2 ) compare treatment beta blocker metoprolol permanent AF .</brief_summary>
	<brief_title>Rate Control Atrial Fibrillation II</brief_title>
	<detailed_description>Atrial fibrillation common cardiac disease , increase incidence prevalence . There two main treatment strategy arrhythmia , rhythm control rate control . As rate control easy achieve major difference outcome find two strategy , consider reasonable initial treatment majority AF patient . Reduced exercise capacity prevalent symptom patient permanent AF . In first Rate control Atrial Fibrillation ( RATAF ) study , demonstrate calcium channel blocker preserve exercise capacity , reduce arrhythmia-related symptom lower level NT-proBNP - whereas beta blocker reduce exercise capacity , reduce arrhythmia-related symptom increase NT-proBNP . These finding relevant large proportion patient permanent AF , suggest calcium channel blocker first drug choice rate control patient without heart failure coronary heart disease . Our result challenge current widespread use beta blocker set . However , follow time RATAF study 3 week , clear effect sustain time . Furthermore , know mechanisms differential effect exercise capacity , arrhythmia relate symptom NT-proBNP level . In RATAF II study investigate whether effect NT-proBNP level , exercise capacity symptom sustain time , explore potential mechanism may explain difference effect . The study provide new insight result relevant everyday clinical practice importance large grow group patient . A total 240 patient include . Eligible patient recruit out-patient clinic participation hospital advertisement local newspaper . After inclusion wash-out period 14 day free drug affect heart rate , patient examine echocardiography , 12-lead ECG ( electrocardiography ) , 24h Holter monitoring , maximal cardiopulmonary exercise test venous blood sample rest , maximal exercise recovery . Perceived arrhythmia relate symptom , quality life level physical activity assess use self-administered questionnaire . Participants randomize computer-generated randomization list , receive one study drug regimen ; metoprolol 100 mg o.d . diltiazem 360 mg o.d . The investigator study personnel blind regard allocate study drug . The participant know study drug assign . Also , study personnel involve examination also able acquire knowledge concern assign study drug , ensure process dosage startup phase , assess adverse event ( AE ) side effect throughout study . Examinations repeat four week six month . All examination perform Department Medical Research , Baerum Hospital ensure standardized procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Above 18 year age Symptomatic , permanent AF least three month duration Resting heart rate â‰¥80 bpm Signed informed consent Congestive heart failure Ischemic heart disease Hypotension ( Systolic blood pressure &lt; 100 mmHg ) Treatment class I III antiarrhythmic drug Severe hepatic renal failure Pregnancy lactation Hypersensitivity contradiction study drug Atrioventricular conduction disturbance Thyrotoxicosis Life limit disease substance abuse may affect participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Rate control atrial fibrillation</keyword>
	<keyword>Beta blocker</keyword>
	<keyword>Calcium channel blocker</keyword>
	<keyword>Permanent atrial fibrillation</keyword>
	<keyword>Management atrial fibrillation</keyword>
	<keyword>Atrial fibrillation biomarkers</keyword>
	<keyword>Arrhythmias , cardiac</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Pathological process</keyword>
	<keyword>Diltiazem</keyword>
	<keyword>Metoprolol</keyword>
	<keyword>Adrenergic Agents</keyword>
	<keyword>Adrenergic Antagonists</keyword>
	<keyword>Adrenergic beta-1 Receptor Antagonists</keyword>
	<keyword>Adrenergic beta-Antagonists</keyword>
	<keyword>Anti-Arrhythmia Agents</keyword>
	<keyword>Antihypertensive Agents</keyword>
	<keyword>Autonomic Agents</keyword>
	<keyword>Cardiovascular Agents</keyword>
	<keyword>Membrane Transport Modulators</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Sympatholytics</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Vasodilator Agents</keyword>
	<keyword>Troponins</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>Biomarkers</keyword>
</DOC>